Ocular Therapeutix (OCUL) Competitors $11.41 +0.35 (+3.16%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$11.44 +0.04 (+0.31%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. RVMD, GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, and TGTXShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Revolution Medicines Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics Ocular Therapeutix (NASDAQ:OCUL) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends. Do analysts recommend OCUL or RVMD? Ocular Therapeutix currently has a consensus price target of $22.13, indicating a potential upside of 93.91%. Revolution Medicines has a consensus price target of $74.64, indicating a potential upside of 59.80%. Given Ocular Therapeutix's higher probable upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Revolution Medicines 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93 Do insiders & institutionals believe in OCUL or RVMD? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is OCUL or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Revolution Medicines' return on equity of -41.78% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Revolution Medicines N/A -41.78%-35.63% Which has more risk and volatility, OCUL or RVMD? Ocular Therapeutix has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Which has better valuation and earnings, OCUL or RVMD? Ocular Therapeutix has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M31.16-$193.51M-$1.28-8.91Revolution Medicines$11.58M754.02-$600.09M-$4.50-10.38 Does the media favor OCUL or RVMD? In the previous week, Ocular Therapeutix had 32 more articles in the media than Revolution Medicines. MarketBeat recorded 39 mentions for Ocular Therapeutix and 7 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.79 beat Ocular Therapeutix's score of 0.43 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 6 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRevolution Medicines beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$2.61B$6.12B$10.58BDividend YieldN/A52.87%5.65%4.69%P/E Ratio-8.9124.2286.9626.71Price / Sales31.16724.90605.88130.98Price / CashN/A172.1237.9061.31Price / Book5.685.3412.556.55Net Income-$193.51M$32.92M$3.31B$277.50M7 Day Performance-8.94%3.90%4.28%2.42%1 Month Performance-16.10%8.79%6.90%8.63%1 Year Performance15.96%-3.79%70.54%31.60% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix4.0127 of 5 stars$11.41+3.2%$22.13+93.9%+16.0%$1.99B$63.72M-8.91230Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeRVMDRevolution Medicines4.293 of 5 stars$46.07+4.9%$74.64+62.0%-1.3%$8.21B$11.58M-10.24250GRFSGrifols3.6343 of 5 stars$9.93+1.1%$10.30+3.7%+11.5%$6.75B$7.81B8.4923,822News CoveragePositive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5196 of 5 stars$100.64+1.5%$106.64+6.0%+99.5%$6.59B$130.13M-33.44140RNAAvidity Biosciences2.5598 of 5 stars$42.63-0.7%$68.32+60.3%-0.6%$6.27B$10.90M-11.97190Positive NewsABVXAbivax3.2642 of 5 stars$83.33+0.6%$102.14+22.6%+758.1%$6.26BN/A0.0061Analyst RevisionLEGNLegend Biotech2.8166 of 5 stars$32.85-1.6%$74.22+125.9%-34.7%$6.16B$627.24M-37.332,609CYTKCytokinetics3.8724 of 5 stars$53.89+6.9%$75.71+40.5%+0.5%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.272 of 5 stars$84.84+4.2%$119.50+40.9%-19.7%$5.87BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.8362 of 5 stars$117.62+0.7%$177.86+51.2%+38.9%$5.83B$385.69M-23.20380Trending NewsAnalyst ForecastAnalyst RevisionTGTXTG Therapeutics4.3897 of 5 stars$36.83+3.7%$48.00+30.3%+65.1%$5.63B$329M99.54290 Related Companies and Tools Related Companies RVMD Competitors GRFS Competitors RYTM Competitors RNA Competitors ABVX Competitors LEGN Competitors CYTK Competitors NUVL Competitors AXSM Competitors TGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts